
 | °ß´â¤ËÂФ¹¤ë¼£ÎÅË¡¤ÎÁªÂò¡¡¡¦¡¦¡¦°ß´â¤ËÂФ¹¤ë¼£ÎÅË¡¤ÎÁªÂò
¡¡StageI(Ia,Ib),·¤ËÂФ¹¤ë¼£ÎÅÊý¿Ë¡¡
¡¡St¡¦¡¦ ¢¡ | 45-07 ¾ |
 |
 | °ß´â¤ËÂФ¹¤ëÊ¢¹ÐÆâ3Éô°ÌÀö¾ôºÙ˦¿Ç¡¡¡¦¡¦¡¦ÂоݤÈÊýË¡
495Îã¡¡
·ë²Ì¡¡
¹Í»¡¡¦¡¦ ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | °ß´â¤Î°ßÁ´Å¦½Ñ¡¡¡¦¡¦¡¦°ßÁ´Å¦½Ñ¡¡
¡¡Ì®´É¤ÎÁö¹Ô°Û¾ï¡¡
¡¡¡¡Gastric-Trunk¤ÎÁö¹Ô¤È½èÍý¡¦¡¦ ¢¡ | ³°²Ê¼ê½Ñ ¾ |
 |
 | °ß´â¤Î°äÅÁ»Ò°Û¾ï¡¡¡¦¡¦¡¦°ß´â¤ÎÁÈ¿¥È¯À¸¤È°äÅÁ»Ò°Û¾ï cerbB2 c-met APC
p53¡¦¡¦ ¢¡ | °ß´â ¾ |
 |
 | °ß´â¤Î²½³ØÎÅË¡¡¡¡¦¡¦¡¦TS-1 FAMTXÎÅË¡¡¡EAPÎÅË¡¡¡FPÎÅË¡¡¡5-FU¡¡ADM¡¡MTX¡¡LV¡¡ ÆüËܤˡ¦¡¦ ¢¡ | °ß´â ¾ |
 |
 | °ß´â¤Î³ÈÂ纬¼£¼ê½Ñ¡¡¡¦¡¦¡¦¼£ÎÅÊý¿Ë
º¸¾åÊ¢Æâ¡Á´Å¦½½Appleby¼ê½Ñ
ç¹Æ¬½½Æó»ØÄ²ÀÚ½ü¡¡
¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | £²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾ |
 |
 | °ß´â¤Î´Îž°Ü¾ÉÎã¤ËÂФ·Low-Dose FPÎÅË¡¤Î°Ý»ýÎÅË¡¤È¤·¤ÆTS-1+CDDPưÃíÎÅË¡¤ò¹Ô¤¤ÁÕ¸ú¤·¤¿2Îã ¢¡ | £²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | °ß´â¤Î¼ðáç¥Þ¡¼¥«¡¼¤È¤½¤Î³èÍÑ¡¡¡¦¡¦¡¦°ß´â¥Ï¥¤¥ê¥¹¥¯´µ¼Ô¤Î¥¹¥¯¥ê¡¼¥Ë¥ó¥°¡¡
¥Ø¥ê¥³¥Ð¥¯¥¿¡¼¡¦¥Ô¥í¥ê·ìÃæ(HP)¹³ÂΡ¡
Êä½õ¡¦¡¦ ¢¡ | ¼ðáç¥Þ¡¼¥«¡¼ ¾ |
 |
 | °ß´â¤Î½Ì¾®¼ê½Ñ¡¡¡ÝŬ±þ¤ÈÌÂÁö¿À·Ð²¹Â¸½Ñ¼°¡Ý ¢¡ | £²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾ |
 |
 | °ß´â¤Î½ÑÁ°¿ÇÃǤοʤáÊý¡¡¡¦¡¦¡¦½é²ó¸¡ºº¤«¤é´â¤Îȯ¸«¤Þ¤Ç¡¡
Æâ»ë¶À¸¡ºº¤Î±üδ¤ÈX¸¡ºº¡¦¡¦
°ß´â¤Î¿¼Ã£ÅÙ¿ÇÃÇ¡¡
¡¡¡¦¡¦¡¦ ¢¡ | £²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾ |
 |
 | °ß´â¤Î¿ȯÀ´Îž°Ü¤ËTS-1ÆâÉþ¤ÈMMCÀÅÃí¤¬Ãø¸ú¤·¤¿1Îã ¢¡ | °ß´â ¾ |
 |
 | °ß´â¤ÎÊ¢¹Ð¶À²¼¼ê½Ñ¡¡¡¦¡¦¡¦Ê¢¹Ð¶À²¼¼ê½Ñ¤ÎŬ±þ
½Ñ¼°¡¡
¡¡¡¦¡¦¡¦
¡¡Ê¢¹Ð¶À²¼°ßÆâÇ´ËìÀÚ½ü½Ñ¡ÊLIM¡Ë
¼ê½Ñ¡¦¡¦ ¢¡ | £²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾ |
 |
 | °ß´â¤ÎÊ¢ËìÇżï¤ËÂФ¹¤ëÊ¢¹ÐÆâÈ¿Éü²½³ØÎÅË¡¤Î¸¡Æ¤ ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | °ß´â¤ÎÊ¢ËìÇżïÀž°ÜÍÛÀÎã¤ËÂФ¹¤ëTS-1¤ÎÍÍÑÀ ¢¡ | °ß´â ¾ |
 |
 | °ß´â¤Îʬ»ÒÉÂÍý³ØÅª¿ÇÃÇ¡¡¡¦¡¦¡¦Ê¬»ÒÉÂÍý³ØÅª¿ÇÃǤȤÏ
¸½¾õ
¿·¤·¤¤Ê¬»ÒÉÂÍý³ØÅª¿ÇÃÇ
¡¡¥Þ¥¤¥¯¥í¥¢¥ì¥¤¤òÍѤ¤¤¿°ÀÅÙ¡¦¡¦ ¢¡ | £··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | ¢¡3732 | ²½³ØÎÅË¡ ¾ |
 |
 | °ß´â¥ê¥ó¥ÑÀឰܤؤβ¹Ç®²½³ØÊü¼ÍÀþ¼£ÎÅ¡¡¡¦¡¦¡¦°ß´â½Ñ¸å¤Î¥ê¥ó¥ÑÀឰܤò¤¤¿¤·¤¿3Î㡦¡¦ | 22²ó¡¡Âç²ñ |
 |
 | °ß´â¥ê¥ó¥ÑÀáÈù¾®Å¾°Ü¡¡¡¦¡¦¡¦ÂоݤÈÎ×¾²¡¡
¡¡£²£µ£²Îã¡Ü£µ£¸Îã
·ë²Ì¡¡
¡¡¥»¥ó¥Á¥Í¥ë¥ê¥ó¥ÑÀḡº÷¡¡
¡¡¡¡Èù¾®Å¾¡¦¡¦ ¢¡ | °ß´â ¾ |
 |
 | °ß´â°ßÁ´Å¦¸åµó¾å¶õIJ¤Î°À¶¹ºõ¤ËÂФ·expandable metallic stent(EMS)¤òÍѤ¤¤Æ¼£ÎŤ·¤¿1Îã ¢¡ | °ß´â ¾ |
 |
 | °ß´â²½³ØÎÅË¡¤Ë¤ª¤±¤ëSecond-Line¤È¤·¤Æ¤ÎWeekly Docetaxel¤ÎÍÍÑÀ ¢¡ | °ß´â ¾ |
 |
 | °ß´â²½³ØÎÅË¡¤Ë¤ª¤±¤ëTaxotere¤Î°ÌÃÖÉÕ¤± ¢¡ | °ß´â ¾ |
 |
 | °ß´â²½³ØÎÅË¡¸åºÆÈ¯À¶»¿å¤ËTS-1-Based Sequential Therapy¤È¤·¤Æ¤ÎTS-1,TaxaneÊ»ÍѲ½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿1¾ÉÎã ¢¡ | °ß´â ¾ |
 |
 | °ß´â´µ¼Ô¤Ë¤ª¤±¤ëñµåºÙ˦Æâ¥µ¥¤¥È¥«¥¤¥ó¤Î¸¡Æ¤¤Èñµå¤ÎHeterogeneity ¢¡ | °ß´â ¾ |
 |
 | °ß´â´Îž°Ü¤ËÂФ·¤ÆTS-1¼£ÎŸå¤Ë5-FU,Adriamycin,Cisplatin(FAP)´ÎưÃí²½³ØÎÅË¡¤ò¹Ô¤Ã¤¿¾ÉÎã ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | °ß´â´Îž°Ü¤ËÂФ¹¤ë´ÎÀÚ½ü¤ÎŬ±þ¡¡¡¦¡¦¡¦ÂоݤÈÊýË¡¡¡
¡¡£·£¹Îã
·ë²Ì¡¡
¹Í»¡¡¡¡¦¡¦ ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | °ß´â´Îž°Ü¤ËÂФ¹¤ëÀÚ½ü¤ÎŬ±þ¤È°ÕµÁ¡¡¡¦¡¦¡¦Âè27²óÆüËÜ´â¶É½êÎÅË¡¸¦µæ²ñ¤Ë¤ÆÈ¯É½¡¡¡¡Âоݡ¨26Îã(ÃËÀ16Î㡦½÷À10Îã¡Ë¡¢Ç¯Îð41¡¦¡¦ ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | °ß´â´Îž°Ü¤ËÂФ¹¤ëưÃí²½³ØÎÅË¡-3ǯ°Ê¾åÀ¸Â¸Îã¤Î¸¡Æ¤- ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | °ß´â´Îž°Ü¤ËÂФ¹¤ëưÃí²½³ØÎÅË¡¤Î¸¡Æ¤¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | °ß´â´Îž°Ü¾ÉÎã¤Ë¤ª¤±¤ë´ÎưÃíÁÕ¸úÎã¤Î¸¡Æ¤¡¡¡¦¡¦¡¦ÂоݤÈÊýË¡¡¡
¡¡Æ±»þÀ´Îž°Ü¾ÉÎã¡¡£±£³£·Îã
¹Í»¡¡¡¡¦¡¦ ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | °ß´â´Îž°Ü¾ÉÎã¤ËÂФ·Í½ËÉŪ´ÎưÃí¤Î͸úÀ¤¬¼¨º¶¤µ¤ì¤¿1Îã ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | °ß´â´Îž°Ü¾ÉÎã¤ËÂФ¹¤ëCPT-11´ÎưÃí²½³ØÎÅË¡¤Î·Ð¸³ ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | °ß´â´Îž°Ü¾ÉÎã¤ËÂФ¹¤ëTS-1¡¦Low-Dose CDDPÊ»ÍÑÎÅË¡¤Î·Ð¸³ ¢¡ | °ß´â ¾ |
 |
 | °ß´â´âÀÊ¢Ëì±ê¤ËÂФ¹¤ëWeekly PaclitaxelÅêͿˡ¤ÎÍÍÑÀ ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | °ß´âºÙ˦³ô¤Ë¤ª¤±¤ë¥Á¥ß¥¸¥ë»À¹çÀ®¹ÚÁǤÎȯ¸½¡¦°äÅÁ»Ò·¿¤È5-Fluoro-5'-Deoxyuridine´¶¼õÀ¤Î¸¡Æ¤ ¢¡ | °ß´â ¾ |
 |
 | °ß´â¼£ÌþÀÚ½ü4ǯ9¤«·î¸å¤Ë¥¤¥ì¥¦¥¹¤Ë¤ÆÈ¯¾É¤·¤¿¸ÉΩÀž°ÜÀ¾®Ä²´â¤Î1ÀÚ½üÎã | 39-01 |
 |
 | °ß´â¼£ÌþÀÚ½ü¸å¤ÎÊä½õ²½³ØÎÅË¡ 5'DFUR+CDDP vs5'-DFURñÆÈ ¢¡ | °ß´â ¾ |
 |
 | °ß´â¼£Îšݼê½Ñ¡¦²½³ØÎÅË¡¡Ý¤ÎÁªÂò´ð½à¡¡¡¦¡¦¡¦Áá´ü°ß´â¡¡
¡¡EMR¡¡Ê¢¹Ð¶À²¼°ßÀÚ½ü½Ñ¡¡¡¦¡¦¡¦
¿Ê¹Ô°ß´â¤ËÂФ¹¤ë½Ñ¼°¤ÎÁªÂò¡¡
¡¡Ã桦¡¦ ¢¡ | £²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾ |
 |
 | °ß´â¼£ÎŤˤª¤±¤ë°äÅÁ»Ò¿·¿¤Î´ØÍ¿¡¡¡¦¡¦¡¦¡¦¤Ï¤¸¤á¤Ë¡¡
¡¦¹³´âºÞ¤ËÂФ¹¤ë responder¡¡¤È¡¡non-responder
¡¦¡¦ ¢¡ | °ß´â ¾ |
 |
 | °ß´â¼£ÎŤˤª¤±¤ë²½³ØÎÅË¡¤ÎÌôºÞ·ÐºÑ³ØÅª¸¡Æ¤ ¢¡ | °ß´â ¾ |
 |
 | °ß´â¼£ÎŤˤª¤±¤ë¿·µ¬¹³´âºÞ¤Îɾ²Á¤È°ÌÃÖÉÕ¤± ¢¡ | °ß´â ¾ |
 |
 | °ß´â¼£ÎŤÎControversy¡¡¡¦¡¦¡¦¤¬¤ó¼£ÎŤÎControversy¡Ý¾Ã²½´ï¤¬¤ó¡¼
Controversy¡§ÏÀÁ衦¡¦ | 30-09 |
 |
 | °ß´â¼£ÎÅ¥¬¥¤¥É¥é¥¤¥ó²þÄû¤Ë¤Ä¤¤¤Æ¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | °ß´â ¾ |
 |
 | °ß´â¼ê½Ñ»þ¤Ë¶öÁ³È¯¸«¤µ¤ì¤¿Ãî¿â»ÒµÜÆâËì¾É¤Î 1 Îã ¢¡ | °ß´â ¾ |
 |
 | °ß´â¼ê½Ñ¾ÉÎã¤Ë¤ª¤±¤ëÊĺ¿¼°»ý³µÛ°ú¥É¥ì¡¼¥ó¤Î·Ð¸³ ¢¡ | °ß´â ¾ |
 |
 | °ß´â½Ñ¸åSchnitzlerž°Ü¤Ë¤è¤ëľIJ¶¹ºõ¤ËÂФ·TS-1¡¤CDDPÊ»ÍѲ½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿1Îã ¢¡ | °ß´â ¾ |
 |
 | °ß´â½Ñ¸å¤Ë¹³·ìÞù¥¿¥ó¥Ñ¥¯¼Á¹³ÂΤˤè¤ëÈóÍÏ·ìÀÍ¢·ìÉûºîÍѤòÄ褷¤¿ 1 Îã ¢¡ | £²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾ |
 |
 | °ß´â½Ñ¸å¤ËÓë²¼¾ã³²¤Çȯ¾É¤·¤¿¶¯Ä¾ÀÀÔÄǹüÁý¿£¾É¤Î 1 Îã ¢¡ | £²·îÂ裴½µ¡§£²£µÆü¡Ê¶â¡Ë ¾ |
 |
 | °ß´â½Ñ¸å¤Î´Î¡¦ÂçÆ°Ì®¥ê¥ó¥ÑÀឰܺÆÈ¯¤È½Ä³Ö¥ê¥ó¥ÑÀáºÆ¡¹È¯¤ËLow-Dose FPÎÅË¡¤¬Ãø¸ú¤·¤¿1Îã ¢¡ | °ß´â ¾ |
 |
 | °ß´â½Ñ¸å¤ÎÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀá¤Èº¸¿Õž°ÜºÆÈ¯¤ËÂФ·¤ÆWeekly Paclitaxel¤Ë¤è¤ëSecond-Line Chemotherapy¤ÇCR¤ÎÆÀ¤é¤ì¤¿1Îã ¢¡ | °ß´â ¾ |
 |
 | °ß´â½Ñ¸å¤ÎÍñÁ㞰ܤËÂФ·¤Æ¶É½êÀ©¸æ¤òÌÜŪ¤Ë¥ê¥ó¥ÑÀá³ÔÀ¶¤òȼ¤¦ÍñÁãŦ½Ð½Ñ¤ò»Ü¹Ô¤·¤¿2¾ÉÎã ¢¡ | °ß´â ¾ |
 |
 | °ß´â½Ñ¸å´µ¼Ô¤Ø¤ÎTS-1»ÈÍѷи³-Feasibility¤Î¸¡Æ¤- | 31-04 |
 |
 | °ß´â½Ñ¸å½Ä³Ö¥ê¥ó¥ÑÀáºÆÈ¯¤Ë¤è¤ëµ¤´É¶¹ºõ¤Ë¥¹¥Æ¥ó¥È+Êü¼ÍÀþ¼£ÎŤ¬ÁÕ¸ú¤·¤¿1Îã ¢¡ | Êü¼ÍÀþ´ØÏ¢ ¾ |
 |
 | °ß´â½Ñ¸å¾ÉÎã¤Ë¤ß¤é¤ì¤¿ EDTA¡Êethylene diamine tetraacetic acid¡Ë°Í¸Àµ¶À·ì¾®Èĸº¾¯¾É¤Î 1 Îã ¢¡ | °ß´â ¾ |
 |
 | °ß´â½Ñ¸å¾ÉÎã¤ËÂФ¹¤ëLow-Dose FPÎÅË¡¤Î¸¡Æ¤ ¢¡ | £··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | °ß´â½Ñ¸å¿ȯÀ´Îž°ÜºÆÈ¯¤ËÂФ·Paclitaxel Weekly´ÎưÃíÎÅË¡¤¬ÁÕ¸ú¤·¤¿1Îã ¢¡ | £²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | ¢¡3726 | ²½³ØÎÅË¡ ¾ |
 |
 | °ß´âÀÚ½ü¸åÊ¢¹ÐÆâ°ä»Ä´âÉÂÁã¤ËÂФ·,TS-1ñºÞ¤ª¤è¤ÓTS-1¡ÜCDDPÊ»ÍÑÎÅË¡¤Ç12¤«·îNC¤ò°Ý»ý¤Ç¤¤¿1Îã ¢¡ | °ß´â ¾ |
 |
 | °ß´âÀÚ½üÎã¤Ë¤ª¤±¤ëOrotate Phosphoribosyltransferase(OPRT)¹ÚÁdzèÀ¡¤ÃÁÇò¤Ë´Ø¤¹¤ëÎ×¾²ÉÂÍý³ØÅª¸¡Æ¤ ¢¡ | 9·î£´½µ¡Ê24Æü¡Ë ¾ |
 |
 | °ß´âÀÚ½üÎã¤Ë¤ª¤±¤ë;ɾõÎã¤È¸¡¿Çȯ¸«Îã¤ÎÈæ³Ó¤«¤é¤ß¤¿¸¡¿Ç¤Î°ÕµÁ ¢¡ | °ß´â ¾ |
 |
 | °ß´âÁÈ¿¥¤Ë¤ª¤±¤ëDihydropyrimidine Dehydrogenase¤Îȯ¸½ ¢¡ | °ß´â ¾ |
 |
 | °ß´âÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀឰܤª¤è¤Ó½Ñ¸å¥ê¥ó¥ÑÀáºÆÈ¯¤ËÂФ¹¤ëÊü¼ÍÀþ¼£ÎŤΰյÁ ¢¡ | °ß´â ¾ |
 |
 | °ß´âƱ»þÀ´Îž°Ü¾ÉÎã¤ËÂФ¹¤ë½¸³ØÅª¼£ÎÅË¡¤Î¸¡Æ¤ ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | °ß´âÇżïÀÉÂÁã¤ËÂФ¹¤ë°ßÀÚ½ü¸å-²¹Ç®²½³ØÎÅË¡¤Î¸¡Æ¤ ¢¡ | 19-Supplement¡¡µ ¾ |
 |
 | °ß´âÊ¢Ë잰ܤËÂФ·Second-Line¤Ç¤ÎPaclitaxelWeeklyÅêÍ¿¤¬ÁÕ¸ú¤·¤¿1Îã ¢¡ | °ß´â ¾ |
 |
 | °ß´âÊ¢ËìÇżï¤Ë¤ª¤±¤ëÊ¢¹ÐÆâ²½³ØÎÅË¡¤ÎÍÍÑÀ¤È¿·µ¬¹³´âºÞ¤Î¹×¸¥ÅÙ ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | °ß´âÊ¢ËìÇżï¤ËÂФ¹¤ë·Ð¸ýTS-1Ê¢¹ÐÆâPaclitaxelÅêÍ¿¤Ë¤è¤êÊ¢¹ÐÆâCR¤òÆÀ¤¿1Îã ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | °ß´âÊ¢ËìÇżï¤ËÂФ¹¤ë»ý³²¹Ç®Ê¢ËìÞõήˡ¤Î¼£ÎŸú²Ì ¢¡ | ²¹Ç®¼£Îо |
 |
 | °ß´âÊ¢ËìÇżï¤ËÂФ¹¤ëÄ㿻Ʃ°µCDDPÊ¢¹ÐÆâ²½³ØÎÅË¡¤Î°ÂÁ´À¤È¸ú²Ì ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | °ß´âÊ¢ËìÇżï¾ÉÎã¤ËÂФ¹¤ëDocetaxel(Taxotere)Ê¢¹ÐÆâÅêÍ¿»þ¤ÎÌôʪưÂ֤ȰÂÁ´À¤Î¸¡Æ¤ ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | °ß´âÊ¢ËìÇżï¾ÉÎã¤ËÂФ¹¤ë¾¯ÎÌCDDPÈ¿ÉüÊ¢¹ÐÆâÅêÍ¿¤Î°ÕµÁ ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | °ß´âÊ¢ËìÇżïÀž°Ü¤Ë¤ª¤±¤ëIP3R¤Î¹âȯ¸½¤Èʬ»ÒɸŪÎÅË¡¤Ø¤Î±þÍÑ ¢¡ | ʬ»ÒɸŪÌô ¾ |
 |
 | °ß´âÊ¢ËìÇżïÀž°Ü¤Ë¤ª¤±¤ëRegIV¤Î¹âȯ¸½ ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | °ß´âÊ¢ËìÇżïÀž°Ü¤Ë¤ª¤±¤ëÄêÎÌPCR¤òÍѤ¤¤¿RegIV¤Îȯ¸½²òÀÏ ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | °ß´âÊ¢ËìÇżïÀž°Ü¤ËÂФ¹¤ë¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³Âηë¹ç¹³´âºÞA7-NCSÊ¢¹ÐÆâÅêÍ¿¤ÈÀÅÌ®ÆâÅêÍ¿¤ÎÈæ³Ó¸¡Æ¤ ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | °ß´âÊ¢ËìÇżïÀž°Ü¿ÇÃǤΤ¿¤á¤Î½ÑÃæ²½³ØÎÅË¡¤Î»ØÉ¸¤È¤Ê¤ë¿·¤·¤¤°äÅÁ»Ò¥Þ¡¼¥«¡¼ ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | °ß´âÍ©Ì禰ßÀÚ½ü½Ñ(³«Ê¢¡Ë¡Ý¾Ã²½´ï¼À´µ¤ËÂФ¹¤ë¥¯¥ê¥Ë¥«¥ë¥Ñ¥¹¤Îɾ²Á ¢¡ | £²·îÂ裴½µ¡§£²£µÆü¡Ê¶â¡Ë ¾ |
 |
 | °ß´âͳÍèž°ÜÀÍñÁã¼ðáç¤ËÂФ¹¤ëUFT,CisplatinÊ»ÍѲ½³ØÎÅË¡ ¢¡ | ÍñÁã´â ¾ |
 |
 | °ß¾®ºÙ˦´â¤Î1Îã¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | °ß´â ¾ |
 |
 | °ß¾®ºÙ˦´â°Û»þÀ´Îž°Ü¤Î1Îã¡¡¡¦¡¦¡¦¡¦¡¦ | 39-02 |
 |
 | °ßÀÚ½ü¸å¤ËȯÀ¸¤·¤¿°Û½êÀ´Ôή¤Ë¤È¤â¤Ê¤¦¸Â¶ÉÀ»éËôΤÎ1Îã ¢¡ | 9·î£²½µ¡Ê£¹Æü¡Ë ¾ |
 |
 | °ßÀü¹¦¤Çȯ¾É¤·CPT-11/CDDPÎÅË¡¤¬ÁÕ¸ú¤·¤¿°ß¾®ºÙ˦´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | °ßÁ°ÄíÉô¤ËȯÀ¸¤·½½Æó»ØÄ²¤ËÖÈÆþ¤·¤¿µðÂç²á·ÁÀ®À¥Ý¥ê¡¼¥×¤Î 1 Îã¡¡ ¢¡ | £²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾ |
 |
 | °ßÁ´Å¦½Ð¸åʹçÉôºÆÈ¯¤ËTS-1¤¬Í¸ú¤À¤Ã¤¿°ß´â¤Î2Îã ¢¡ | °ß´â ¾ |
 |
 | °ßÁ´Å¦½Ñ¸åTS-1¤ò·Ð´É±ÉÍÜ¥«¥Æ¡¼¥Æ¥ë¤«¤éÅêÍ¿¤·¤¿°ß´â¤Î1Îã ¢¡ | 2006ǯ1·î ¾ |
 |
 | °ßIJ¼ê½Ñ¸å¤Î¥É¥ì¡¼¥ó¤ÏɬÍפ« ¡Ý¿Í¤Ëʹ¤±¤Ê¤¤ÁÇËѤʵ¿Ì䡦3 ¢¡ | £²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾ |
 |
 | °ßIJ¼ê½Ñ¸å¤Î·ÐÉ¡°ß´É¤ÏɬÍפ«¡¡¡Ý³°²Ê¤Î¾ï¼±¡¦Èó¾ï¼±¡½¿Í¤Ëʹ¤±¤Ê¤¤ÁÇËѤʵ¿Ì䡦5 ¢¡ | £²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾ |
 |
 | °ßž°Ü¤ò¤¤¿¤·¤¿ PTH¡ÝrP »ºÀ¸Æý´â¤Î 1 Îã ¢¡ | £²·îÂ裴½µ¡§£²£µÆü¡Ê¶â¡Ë ¾ |
 |
 | °ßž°Ü¤ò¤¤¿¤·¤¿Æý´â¤Î1Îã-¸¶È¯À¤ª¤è¤Óž°ÜÀBorrmann4·¿°ß´â¤ÎÌȱÖÀ÷¿§¤Ë¤è¤ë´ÕÊ̤ˤĤ¤¤Æ- ¢¡ | °ß´â ¾ |
 |
 | °ßÇ´Ëì²¼¼ðáçÁü¤òÄ褷¤¿Í·ÔÀ¡¦´Î³°È¯°é·¿ ´Î·ì´É¼ð¤Î1Îã ¢¡ | 9·î£²½µ¡Ê£¹Æü¡Ë ¾ |
 |
 | °ßÊɳ°Àȯ°é¤ò¼¨¤·¤¿µðÂç GIST ¤Î 1 Îã ¢¡ | GIST ¾ |
 |
 | °äÅÁ¥«¥¦¥ó¥»¥ê¥ó¥°-ôÅö¥Ê¡¼¥¹¤ÎΩ¾ì¤«¤é- ¢¡ | 2006ǯ1·î ¾ |
 |
 | °äÅÁ°åÎÅ-´âÀìÌçɱ¡°å»Õ¤ÎΩ¾ì¤«¤é-¡¡¡¦¡¦¡¦²È²À¼ðáç¤ÎÆÃħ¡¡°äÅÁ¥«¥¦¥ó¥»¥ê¥ó¥°¤Î¸½¾õ¡¡°äÅÁ¿ÇÎŤÎŸ˾¤ÈÌäÂêÅÀ¡¦¡¦ ¢¡ | 2006ǯ1·î ¾ |
 |
 | °äÅÁ»Ò²òÀϤËÂФ¹¤ë²¤ÊƼçÍ×¹ñ¤Î¸øÅªµ¬À©¤Î¸½¶· ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | °äÅÁ»Ò¸¡ºº-´ë¶È¤ÎΩ¾ì¤«¤é-Êñ³çŪ°äÅÁ»Ò¿ÇÎÅ¥µ¥Ý¡¼¥È¥·¥¹¥Æ¥à¤Ë¤ª¤±¤ë°äÅÁÀ¼ðáç¤Î°äÅÁ»Ò¸¡ºº ¢¡ | 2006ǯ1·î ¾ |
 |
 | °äÅÁ»Ò¸¦µæ¤Èʬ»ÒɸŪ¼£ÎÅÌô¡¡¡¦¡¦¡¦³µÏÀ¡¡¡¡¡¡¡¡
¤Ï¤¸¤á¤Ë¡¡¡¡
µ.¤¬¤óºÙ˦¤Îʬ»Òµ¡¹½¤Î¸¡Æ¤¡¡1.´â¤ÎÁý¿£µ¡¹½¤Î²òÀϤȤ½¡¦¡¦ ¢¡ | ʬ»ÒɸŪÌô ¾ |
 |
 | °äÅÁ»Ò¼£ÎŤμºݡ¡¡¦¡¦¡¦Ad5CMVp53 ÇÙ´â¿ÇΚݺǶá¤ÎÏÃÂê¡Ý
ÀÚ½üÉÔǽÈ󾮺Ù˦Çٴ⡡ƬðôÉô´â¡¡¼«»¦°äÅÁ»Ò¡¦¡¦ ¢¡ | ÇÙ´â ¾ |
 |
 | °äÅÁ»Ò¿·¿(SNPs)¸¦µæ¤ÈÀ¸Ì¿ÎÑÍý¡¡¡¦¡¦¡¦°äÅÁ»Ò¿·¿(SNP):¥ª¡¼¥À¡¼¥á¥¤¥É°åÎŤؤαþÍÑ¡¦¡¦ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | °äÅÁ»Ò¿·¿¤È¤¬¤óȯÀ¸¥ê¥¹¥¯¡¡¡¦¡¦¡¦¤¬¤ó±Ö³Ø¤ÎºÇ¿·¾ðÊó¡¡¡¡¡¡
¤Ï¤¸¤á¤Ë¡¡¡¡
µ.°äÅÁ»Ò¿·¿¤È¤Ï¡¡¡¡
¶.¤¬¤óȯÀ¸µ¡½ø¤«¡¦¡¦ ¢¡ | ¿©À¸³è ¾ |
 |
 | °äÅÁ»Ò¿·¿¤ÈÁÏÌô¡¡¡¦¡¦¡¦°äÅÁ»Ò¿·¿(SNP):¥ª¡¼¥À¡¼¥á¥¤¥É°åÎŤؤαþÍÑ¡¦¡¦ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | °äÅÁ»Ò¿·¿¤ÈÌôºÞ±þÅúÀ¡¡¡¦¡¦¡¦ÌôʪÂå¼Õ¹ÚÁǰäÅÁ»Ò·²SNP¾ðÊó¤Î´ðÈ×À°È÷¡¦¡¦ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | °äÅÁ»Ò¿·¿¤Ë¤Ä¤¤¤Æ¡¾¸¦µæ¤Î¸½¾õ¡¡¡¦¡¦¡¦¤Ï¤¸¤á¤Ë¡¡
°äÅÁ»Ò¿·¿¤ÎÄêµÁ¡¡
¿·¿¥Þ¡¼¥«¡¼¤Î¼ïÎà¤È¸¡½ÐÊýË¡¡¡
°äÅÁ»Ò¿·¿¤Î²òÀÏÊý¡¦¡¦ ¢¡ | ¸¡ºº ¾ |
 |
 | °äÅÁ»Ò¿·¿¤òÍøÍѤ·¤¿¼À´µ°äÅÁ»Ò¸¦µæ¤ÎÍýÏÀ¡¡¡¦¡¦¡¦°äÅÁ»Ò¿·¿¡ÊSNP):¥ª¡¼¥À¡¼¥á¥¤¥É°åÎŤؤαþÍÑ¡¦¡¦ | 29-10 |
 |
 | °äÅÁ»Ò¿·¿²òÀϸ¦µæ¤Î°ÕµÁ¤È21À¤µª¤Ë¤ª¤±¤ë´â¼£ÎŤؤÎÄó¸À ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | °äÅÁ¿ÇÎÅ-°åÎÅ»ÜÀߤˤª¤±¤ë¥ì¥¸¥¹¥È¥é¡¼¤ÎɬÍ×À- ¢¡ | 2006ǯ1·î ¾ |
 |
 | °äÅÁÀµå¾õÀÖ·ìµå¾É¤ò¹çÊ»¤·¤¿ç¹¿À·Ð¾ä¼ð¤Î1Îã ¢¡ | 8·îÂè2½µ(5Æü¡Ë ¾ |
 |
 | °äÅÁÀ¼ðá縦µæ¤Î¸½¾õ¤È¾Íè-¸¦µæ¼Ô¤ÎΩ¾ì¤«¤é- ¢¡ | ÂçIJ´â ¾ |
 |
 | °äÅÁÀÂçIJ´â¤Î´âͽËɤθ½¾õ¤È¾Íè¤ÎŸ˾¡¡¡¦¡¦¡¦´â¤ÎͽËÉÂкö¡¡°ì¼¡Í½ËÉ¡§È¯´âͽËÉ¡¡Æó¼¡Í½ËÉ¡§´â»àͽËÉ¡¦¡¦ ¢¡ | ÂçIJ´â ¾ |
 |
 | °äÅÁÀÈó¥Ý¥ê¥Ý¡¼¥·¥¹ÂçIJ´â²È·Ï¤Ë¤ª¤±¤ë»ÒµÜÆâËì´â¤Î½ÅÍ×À ¢¡ | »ÒµÜ´â ¾ |
 |
 | °å»Õ¼çƳ¼£¸³¤È¿·¤·¤¤Ìô»öË¡¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | À©ÅÙ¡¦Ë¡Î§¡¦Åý·× ¾ |
 |
 | °åÎŤˤª¤±¤ë¸Ä¿Í¾ðÊ󳫼¨¤ÈÊݸ¡¦¡¦¡¦¹ÔÀ¯¤ÎΩ¾ì¤«¤é¤Î¾ðÊ󳫼¨¤ÎɬÍ×À
´Ç¸î¶È̳¤È¾ðÊ󳫼¨¡¡
¸Ä¿Í¾ðÊóÊݸ
¿ÇΞðÊ󡦡¦ ¢¡ | 9·î£²½µ¡Ê£¹Æü¡Ë ¾ |
 |
 | °åÎÅ»ö¸Î¤ÎËɻߤΤ¿¤á¤Ë —¤½¤Î¼ÂÂÖ¤ÈÄó¸À— ¢¡ | 9·î£²½µ¡Ê£¹Æü¡Ë ¾ |
 |
 | °åÎÅ»ö¸ÎʶÁèÁý²Ã¤ÎÇØ·Ê¤òõ¤ë¡½´µ¼Ô¦ÊÛ¸î»Î¤Î»ëÅÀ¤«¤é¡½ ¢¡ | £±£°·î£±Æü£Õ£Ð ¾ |
 |
 | °åÎÅÀ©ÅÙ²þ³×¤Ë¤ª¤±¤ëº®¹ç¿ÇÎŤΰյÁ¡¡¡¦¡¦¡¦°åÎÅÊݸ±À©Å٤γµÍ×
¡¡¡¦¡¦¡¦
¡¡»ÅÁȤߡ¡
¡¡¡¦¡¦¡¦
¡¦¡¦¡¦¡¦¡¡¡¦¡¦ ¢¡ | À©ÅÙ¡¦Ë¡Î§¡¦Åý·× ¾ |
 |
 | °ìÈÌɱ¡¤Ë¤ª¤±¤ë´ËÏÂ¥±¥¢¥Á¡¼¥à¤ÎÌò³ä¡¡¡¦¡¦¡¦´ËÏÂ¥±¥¢¥Á¡¼¥à¤ÎÌò³ä ¡¡
¤¬¤óáÖÄ˼£ÎÅ¡¡
áÖÄËɾ²Á¡¡
¥ª¥Ô¥ª¥¤¥É¤ÎÉþÌô»ØÆ³¡¡
¥³¡¦¡¦ ¢¡ | áÖÄË¡¦´ËÏ ¾ |
 |
 | ±¢·Ôž°Ü¤·¤¿ÇÙ٨ʿ¾åÈé´â¤Î1Îã¡¡¡¦¡¦¡¦¾ÉÎã 57ºÐÃËÀ ±¢·Ôž°Ü ³¤ÌÊÂΞ°Ü¡¡
¹Í»¡¡¡¡¦¡¦ ¢¡ | ٨ʿ¾åÈé´â ¾ |
 |
 | ±¦°ßÂçÌÖÆ°Ì®¤ò»ÈÍѤ·¤¿´§¾õư̮¥Ð¥¤¥Ñ¥¹¼ê½Ñ¸å¤Î°ß´â¤ËÂФ·°ßÀÚ½ü½Ñ¤ò»Ü¹Ô¤·¤¿3Îã | 39-02 |
 |
 | ±¦´ÎÀÅÌ®ËÜ´´Ä¾¾å¤Î´ÎºÙ˦´â¤Ë¥Þ¥¤¥¯¥íÇȶŸÇÎÅË¡¤ò¹Ô¤¤Ä¹´üÀ¸Â¸Ãæ¤Î1Îã ¢¡ | ´Î¡´â ¾ |
 |
 | ±¦¼¼ÆâȯÀ¸¤·¤¿°ÀÀþ°ÝÀÁÈ¿¥µå¼ð¤Î1Îã¡¡¡¦¡¦¡¦¾ÉÎã¡¡71ºÐ½÷¡¡
¹Í»¡¡¡¡¦¡¦ ¢¡ | £¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾ |
 |
 | ±¦¿´Ë¼¤Ë¼ðáçÀò¤¬Ã£¤·¤¿´ÎºÙ˦´â¤ËÂФ¹¤ë´ÎÀÚ½ü½Ñ¤Î1Îã | 39-03 |
 |
 | ±¦ðôÉô¡¦º¿¹ü¾å¥ê¥ó¥ÑÀáºÆÈ¯¡¦±¦²¼³Ü¹üž°Ü¤ËÂФ·Biweekly Docetaxel¤È¹âÍÑÎÌToremifene¤ÎÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿ºÆÈ¯Æý´â¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | ±ÉÍܾ㳲¤È±ÉÍÜɾ²Á¡¡¡¦¡¦¡¦³°²Ê¤Ë¤ª¤±¤ë±ÉÍÜ´ÉÍý¡¡
±ÉÍÜɾ²ÁË¡
±ÉÍÜÊäµë¤ÎÁªÂò¤È´ÉÍý¼ê½ç
ÀѶËŪ¤ÊÂå¼Õ´ÉÍý¤Î¸ú¡¦¡¦ ¢¡ | áÖÄË¡¦´ËÏ ¾ |
 |
 | ±ê¾ÉÀÆý´â -ºÇ¶á¤Î»ëÅÀ¤«¤é-¡¡¡¦¡¦¡¦ÄêµÁ¤ÈÉÑÅÙ
³Æ¼ï¥Ð¥¤¥ª¥Þ¡¼¥«¡¼¤È¤½¤Îư¸þ
´ðËÜŪ¼£ÎŤÎÊÑÁ«¤ÈÀ®ÀÓ
¶É½êư̮Æâ¹³´â²½¡¦¡¦ ¢¡ | £¸·î£±Æü ¾ |
 |
 | ±ê¾ÉÀÆý´â Á´¹ñ¥¢¥ó¥±¡¼¥È·ë²Ì¡¡¡¦¡¦¡¦ÂоݤÈÊýË¡¡¡
·ë²Ì¡¡¼ÁÌä¡¡
½¸ÀÑ¡¡·ë²Ì¡¡¹Í»¡¡¦¡¦ ¢¡ | £¸·î£±Æü ¾ |
 |
 | ±ê¾ÉÀÆý´â¤ËÂФ¹¤ë²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤª¤è¤ÓÊü¼ÍÀþñÆÈ¼£ÎŤÎ2¾ÉÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ±ó³Öž°Ü¤òͤ¹¤ëIV´ü¤ª¤è¤ÓºÆÈ¯È󾮺Ù˦ÇÙ´â¤ËÂФ¹¤ë²¹Ç®²½³ØÎÅË¡¤Î¼£ÎÅÀ®ÀÓ ¢¡ | 21-Supplement µ ¾ |
 |
 | ±ó³Öž°Ü¥ê¥ó¥ÑÀ᤬½Ñ¸åLevofolinate(l-LV)/5-Fluorouracil(5-FU)ÎÅË¡¤ÇCR¤È¤Ê¤Ã¤¿Ä¾Ä²´âÀÚ½üÎã¤Î1Îã ¢¡ | ·ëIJ´â ¾ |
 |
 | ±óÀÖ³°Àþ²¹Ç®¼£ÎŤˤè¤ë¥ê¥ó¥Ñµå¤Ë¤ª¤±¤ëHsp70¤ÎͶƳ | 21-4 |
 |
 | ±óÀÖ³°Àþ²¹Ç®ÎÅË¡¤Ë¤è¤ëµ¤Ê¬¥×¥í¥Õ¥¤¡¼¥ë¼ÜÅÙ(POMS:Profile¡¡of¡¡Mood¡¡State)¸¡ºº¤«¤é¤ß¤¿¿´Íý³ØÅªÊѲ½ | 21-4 |
 |
 | ±óÀÖ³°ÀþÁ´¿È²¹Ç®²Ã²¹ÁõÃÖ(Smarty)¤Ë¤è¤êͶȯ¤µ¤ì¤ëHSP70¤ÎưÂ֤ȱ¿Æ°Ç½¥«¥Ø¤Î±Æ¶Á ¢¡ | 18-Supplement ¾ |
 |
 | ±ö»À¥²¥à¥·¥¿¥Ó¥ó ( GEM ) ÅêÍ¿Ãæ¤ÎÀÚ½üÉÔǽ繴â¤ËȯÀ¸¤·¤¿ÇíÎ¥À¿©Æ»±ê¤Î1Îã ¢¡ | 8·îÂè2½µ(5Æü¡Ë ¾ |
 |
 | ±ö»À¥²¥à¥·¥¿¥Ó¥ó¤òÊ»ÍѤ·¤¿ÀÚ½üÉÔǽµÚ¤ÓºÆÈ¯ç¹´â¤ËÂФ¹¤ë²¹Ç®²½³ØÎÅË¡¤Î¸¡Æ¤ ¢¡ | 18-Supplement ¾ |
 |
 | ±ö»À¥é¥â¥»¥È¥í¥ó(¥Ê¥¼¥¢(R)Ãí¼Í±Õ)¤Î»ÔÈθå¤Ë¤ª¤±¤ë°ÂÁ´À¤È͸úÀ -»ÈÍÑÀ®ÀÓÄ´ºº·ë²Ì¤è¤ê- ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | ²£¹Ô·ëIJ¶¹ºõ¤ò¤¤¿¤·¤¿inflammatory myofibroblastic tumor¤Î1Îã ¢¡ | £³·îÂ裲½µ¡§£±£²Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | ²£¹Ô·ëIJ¿»½á¤Ë¤è¤ë²¼·ì¤ò¼çÁʤȤ·¤ÆÈ¯¾É¤·¤¿ç¹ÈøÉô´â¤Î1Îã ¢¡ | £³·îÂ裴½µ¡§£²£¶Æü(ÅÚ¡Ë Â¾ |
 |
 | ²£Ìæ¶ÚÆù¼ð ¡Ý¾®»ù¸Ç·Á¼ðáç¤Î¼£ÎÅÀïά¡¡¡¦¡¦¡¦ÁÈ¿¥Ê¬Îà¡¡
¡¡ÂÛ»ù·¿,¤Ö¤É¤¦Æù¼ð·¿,Ë¿î·ÁºÙ˦·¿,˦Áã·¿,¿·Á·¿¡¡
½é²ó¶É½ê¼£Îšʼꡦ¡¦ ¢¡ | £±£°·î£±Æü£Õ£Ð ¾ |
 |
 | ²£Ìæ¶ÚÆù¼ð¤Î³°²Ê¼£ÎÅÊý¿Ë¡¡¡¦¡¦¡¦ÂоݤÈÊýË¡¡¡¡¡Ç¯Îð8¥ö·î~14ºÐ 8Îã¡¡
¡¡²£Ìæ¶ÚÆù¼ð¡¡³°²Ê¼£ÎÅ¡¡
¡¡¸¶È¯Éô°Ì¡¡Âδ´¡¦¡¦ ¢¡ | £¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾ |
 |
 | ²£Ìæ¶ÚÆù¼ð¤Î¼£ÎÅ¡¾²£Ìæ¶ÚÆù¼ð¤ËÂФ¹¤ëÀ¤³¦¤ª¤è¤Ó¤ï¤¬¹ñ¤Ë¤ª¤±¤ë¥°¥ë¡¼¥×¥¹¥¿¥Ç¥£¤Î¸½¶·¤È¾Íè¤ÎÊý¸þÀ¡¾ ¢¡ | £´·îÂ裱½µ¡§£²Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | ²¤ÊƤˤª¤±¤ëÃÀƻ繴ⲽ³ØÎÅË¡¤Î¸½¶·¡¡¡¦¡¦¡¦¤¬¤ó¼£ÎźÇÁ°Àþ¡¼ÃÀÆ»¡¢ç¹´â¤Î¥¹¥¿¥ó¥À¡¼¥É¼£ÎŤϤ¢¤ë¤Î¤«¡Ý¡¡¡¡
µ.ç¹´â¤ËÂФ¹¤ë²½³ØÎÅË¡¡¦¡¦ ¢¡ | ç¹Â¡´â ¾ |
 |
 | ²«áÕ¤òȼ¤Ã¤¿ÃÀ´ÉÆâȯ°é·¿´ÎºÙ˦´â´µ¼Ô¤ËÂФ¹¤ëPGE1Ê»ÍÑ´ÎÆ°Ãí²½³ØÎÅË¡¤Î1Îã ¢¡ | Êü¼ÍÀþ´ØÏ¢ ¾ |
 |
 | ²¹Àô¤òÍѤ¤¤¿·ò¹¯Áý¿Ê¤È²¹Ç®ÎÅË¡¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | 21-Supplement µ ¾ |
 |
 | ²¹Ç®¡¦Êü¼ÍÀþ¡¦²½³ØÊ»ÍÑÎÅË¡¤Ë¤ÆÃø¸ú¤ò¼¨¤·¤¿ðôÉôµðÂç¼ðáç¤Î°ìÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®¡¦Êü¼ÍÀþ¡¦²½³ØÊ»ÍÑÎÅË¡¤Ë¤è¤ëÃÀÆ»´â¤Î°ì¼£ÎÅÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®²½³ØÊü¼ÍÀþ¼£ÎŤ¬Ãø¸ú¤·¤¿°ß´âºÆÈ¯¤Î2Îã | 21-3 |
 |
 | ²¹Ç®²½³ØÊü¼ÍÀþ¼£ÎŤˤè¤êµßºÑ¤Ç¤¤¿¿©Æ»´âÊü¼ÍÀþ¼£ÎÅ¸åºÆÈ¯¤Î1Îã | 21-3 |
 |
 | ²¹Ç®²½³ØÊü¼ÍÀþÎÅË¡¤¬ÁÕ¸ù¤·¤¿¶»ÊÉ¿»½á·¿ÇÙÀíÉô¼ðáç¤Î1Îã ¢¡ | 19-Supplement¡¡µ ¾ |
 |
 | ²¹Ç®²½³ØÊü¼ÍÀþÎÅË¡¤Çµ¤´É»Ù¡ÝÇ١ݶ»¹ÐÁé¤ò·ÁÀ®¤·¤¿ÇÙž°Ü¤Î1Îã | 21-3 |
 |
 | ²¹Ç®²½³ØÊü¼ÍÀþÎÅË¡¤ÇĹ´üÀ©¸æÃæ¤ÎðôÉô¥ê¥ó¥ÑÀឰܤÎ2¾ÉÎã ¢¡ | 18-Supplement ¾ |
 |
 | ²¹Ç®²½³ØÊü¼ÍÀþÎÅË¡¤Ë¤è¤êÁÈ¿¥³ØÅªCR¤òÆÀ¤¿¿Ê¹ÔľIJ´â¤Î1Îã ¢¡ | ²¹Ç®¼£Îо |
 |
 | ²¹Ç®²½³ØÎÅË¡¤¬°ì»þÁÕ¸ú¤·¤¿Ëö´üç¹´â¤Î1Îã¡¡¡¦¡¦¡¦¡¦¡¦ | 22²ó¡¡Âç²ñ |
 |
 | ²¹Ç®²½³ØÎÅË¡¤¬ÁÕ¸ù¤·¤¿¿Ê¹Ô´ÎºÙ˦´â¤Î1Îã¡¡¡¦¡¦¡¦¡¦¡¦ | 22²ó¡¡Âç²ñ |
 |
 | ²¹Ç®²½³ØÎÅË¡¤¬ÁÕ¸ù¤·¤¿¿Õ´âÇÙž°Ü¤Î1Îã¡¡¡¦¡¦¡¦¡¦¡¦ | 21-3 |
 |
 | ²¹Ç®²½³ØÎÅË¡¤¬ÁÕ¸ù¤·¤¿Ä¾Ä²´â¤Î°ìÎã¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | 21-Supplement µ ¾ |
 |
 | ²¹Ç®²½³ØÎÅË¡¤Î½é´ü·Ð¸³¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | 21-Supplement ¶ ¾ |
 |
 | ²¹Ç®¼£ÎŸå7ǯ·Ð²á´Ñ»¡Ãæ¤Î°À¿À·Ðç±¼ð¾ÉÎã-MRl½ê¸«¤«¤é- ¢¡ | 19-Supplement¡¡¶ ¾ |
 |
 | ²¹Ç®Ê»ÍѲ½³ØºÉÀòÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿´ÎºÙ˦´â¤Î¾ÉÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»ÍѲ½³ØÎÅË¡¤Ë¤è¤ê̵ÉÂ5ǯÀ¸Â¸¤ò²Ì¤¿¤·¤¿ºÆÈ¯»ÒµÜ´â¤Î°ìÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»Íѽ¸³ØÅª¼£ÎŤ¬ÁÕ¸ú¤·¤¿¿Ê¹ÔÀå´â¡¦À岹¸¼£ÎÅÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |